Physician profile
Arron Smith
NPI 1558759423
$2,314.19
in general payments reported to CMS, 2019-2025
17 companies · $750 in 2025
The $750 reported for 2025 was more than what 75% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $536 · 2022: $539 · 2023: $489 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,239.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $423.66 | 2021-2023 | Camzyos |
| Paragonix Technologies, INC. | $313.78 | 2025 | Sherpapak |
| Bridgebio Pharma, INC. | $287.57 | 2025 | Attruby |
| Novartis Pharmaceuticals Corporation | $254.18 | 2021-2023 | |
| United Therapeutics Corporation | $248.99 | 2022-2025 | Remodulin |
| Amgen INC. | $199.56 | 2021-2023 | Repatha |
| Abbott Laboratories | $183.10 | 2021-2023 | Cardiomems |
| Astrazeneca Pharmaceuticals LP | $99.41 | 2021-2025 | Wainua, Brilinta |
| Alnylam Pharmaceuticals INC. | $78.41 | 2021-2022 | |
| Pfizer INC. | $49.69 | 2021 | |
| Boston Scientific Corporation | $46.90 | 2022 | |
| Merck Sharp & Dohme LLC | $24.13 | 2023 | Belsomra |
| Actelion Pharmaceuticals US, INC. | $23.36 | 2023 | Uptravi, Opsumit |
| Regeneron Healthcare Solutions, INC. | $22.53 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.67 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $20.01 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arron Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.